Merck & Co., Inc. MRK
Revenue Intelligence Report • 45 quarters of SEC filing data • Updated 2026-03-06
Merck & Co., Inc. demonstrates strong revenue generation capabilities, with $1 of R&D spending yielding $1.51 in long-run revenue and $1 of SG&A spending producing $3.35. The company recently reported quarterly revenue of $16.4 billion, reflecting a solid holdout test performance with only a 4.4% error in predictions. Looking ahead, Merck forecasts a slight decline in FY revenue to $65 billion, representing a 0.2% year-over-year decrease. Despite this modest outlook, the company's efficient spending strategies suggest a robust foundation for future growth.
Revenue Forecast
Quarterly Detail
| Quarter | Model Forecast | Actual | 95% Range | YoY Growth | Status |
|---|---|---|---|---|---|
| Q4 2025 | $16B | $16B | $14B – $18B | +0.3% | ✓ In range |
| Q2 2026 | $16B | $13B – $19B | +5.7% | ||
| Q3 2026 | $16B | $12B – $20B | +1.4% | ||
| Q4 2026 | $17B | $13B – $21B | -3.3% | ||
| Q1 2027 | $16B | $11B – $20B | -4.0% |
How Spending Drives Revenue
Want this analysis for your portfolio?
I build custom revenue intelligence reports for investors and companies using SEC filing data, econometric modeling, and AI-powered insights.
Get in Touch